$4.19▴ 0.00%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Kalaris Therapeutics, Inc. 's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days2 articles
1 bullish0 neutral1 bearish
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.